TW202410893A - 用於治療t細胞淋巴瘤之結合治療 - Google Patents

用於治療t細胞淋巴瘤之結合治療 Download PDF

Info

Publication number
TW202410893A
TW202410893A TW111142283A TW111142283A TW202410893A TW 202410893 A TW202410893 A TW 202410893A TW 111142283 A TW111142283 A TW 111142283A TW 111142283 A TW111142283 A TW 111142283A TW 202410893 A TW202410893 A TW 202410893A
Authority
TW
Taiwan
Prior art keywords
cell lymphoma
composition
decitabine
lymphoma
cell
Prior art date
Application number
TW111142283A
Other languages
English (en)
Chinese (zh)
Inventor
馬丁 約翰 席斯
喬治 艾伯特 瓦德
哈洛德 基爾
阿拉姆 歐岡塞
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202410893A publication Critical patent/TW202410893A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111142283A 2022-08-31 2022-11-04 用於治療t細胞淋巴瘤之結合治療 TW202410893A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263374137P 2022-08-31 2022-08-31
US63/374,137 2022-08-31

Publications (1)

Publication Number Publication Date
TW202410893A true TW202410893A (zh) 2024-03-16

Family

ID=84359488

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142283A TW202410893A (zh) 2022-08-31 2022-11-04 用於治療t細胞淋巴瘤之結合治療

Country Status (9)

Country Link
US (1) US20240082286A1 (cg-RX-API-DMAC7.html)
EP (1) EP4580635A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025529240A (cg-RX-API-DMAC7.html)
KR (1) KR20250053870A (cg-RX-API-DMAC7.html)
AU (1) AU2022476674A1 (cg-RX-API-DMAC7.html)
CA (1) CA3266274A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025002312A (cg-RX-API-DMAC7.html)
TW (1) TW202410893A (cg-RX-API-DMAC7.html)
WO (1) WO2024047394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
LT4069254T (lt) * 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną

Also Published As

Publication number Publication date
EP4580635A1 (en) 2025-07-09
WO2024047394A1 (en) 2024-03-07
AU2022476674A1 (en) 2025-04-17
MX2025002312A (es) 2025-04-02
KR20250053870A (ko) 2025-04-22
JP2025529240A (ja) 2025-09-04
US20240082286A1 (en) 2024-03-14
CA3266274A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
US20230364086A1 (en) Combination therapies with ehmt2 inhibitors
US12208141B2 (en) Anti-cancer nuclear hormone receptor-targeting compounds
US7479485B2 (en) Method of treating arrhythmias
CN115698014A (zh) 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物
US9464093B2 (en) Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
CN116113406B (zh) Gas41抑制剂及其使用方法
RS64936B1 (sr) Metodi lečenja hematoloških maligniteta korišćenjem 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benz il)amino-)izoindolin 1,3-diona
JP2024542248A (ja) Fgfr阻害剤とkras阻害剤を含む併用療法
US20240082286A1 (en) Combination therapies for treatment of t-cell lymphomas
US20250186451A1 (en) Methods of treating cancer with iap antagonist compounds and combination therapies
TW201725042A (zh) 用於治療癌症及發炎病症之jak抑制劑與syk抑制劑之組合
CN1461219A (zh) 非镇静巴比土酸盐化合物用作神经保护剂
JP2022502378A5 (cg-RX-API-DMAC7.html)
JP2014513104A (ja) Pi3k/mtorのピリドピリミジノン阻害剤を用いたリンパ腫の治療方法
HK1219893A1 (zh) 治療長qt綜合征的化合物和方法
JP2025525058A (ja) ウイルス感染の処置のためのrock2阻害剤
AU2018379230A1 (en) Treatment of RSV with combination product
CN120112288A (zh) 用于治疗肿瘤的药物组合、药物组合物及其用途
JP2024539641A (ja) 癌の治療に使用するための変異retキナーゼの阻害剤
TW202608439A (zh) 治療具有asxl1突變之個體之癌症的方法
HK40057712B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof
HK1229250A1 (en) Methods for treating cancers
HK1229250B (en) Methods for treating cancers